Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs
Company strengthens IGALMI™market exclusivity through receipt of two Notices of Allowance
https://www.biospace.com/article/releases/bioxcel-therapeutics-provides-update-on-recent-developments-for-late-stage-clinical-programs-and-expansion-of-ip-portfolio-for-igalmi-dexmedetomidine-sublingual-film/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.